How does the FDA's new bile duct cancer drug Lyrfigtu actually work?

Lyrfigtu selectively and irreversibly blocks altered FGFR2 in certain advanced bile duct cancers. Molecular testing is what identifies the patients whose tumors carry the target.

Lyrfigtu (lirafugratinib) is an FDA-approved second-line option for advanced cholangiocarcinoma—bile duct cancer—with an FGFR2 fusion or rearrangement. The oral precision drug binds FGFR2 irreversibly and selectively, including some resistance mutations, while sparing related FGFR forms; that design aims to reduce off-target toxicity compared with older pan-FGFR medicines, although the drug still carries important eye, phosphate, and other safety risks. In the Phase 1/2 ReFocus trial, 45.7% of patients had a confirmed objective response, with a reported median response duration of 11.8 months.

The practical lesson begins before treatment: molecular testing at diagnosis is what finds the FGFR2 alteration and makes a match possible. This is an early evidence base, not proof of a cure; follow-up and additional trials are still defining long-term benefit and use after other FGFR drugs.